|
Real-time Estimate
Cboe BZX
19:02:02 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.660 USD | +3.10% |
|
-52.19% | -100.00% |
| 10-08 | Top Premarket Decliners | MT |
| 08-05 | Top Premarket Decliners | MT |
Company Valuation: China SXT Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | - | - | - | 32.93 | 1.425 |
| Change | - | - | - | - | - | -95.67% |
| Enterprise Value (EV) 1 | - | - | - | - | 15.68 | -25.78 |
| Change | - | - | - | - | - | -264.37% |
| P/E | -51,972,996,639x | -495,799,340x | -130,093,653x | -11,542,178x | - | - |
| PBR | - | - | - | - | 2.13x | - |
| PEG | - | -331,597x | 1,593,921.8x | -68,247x | - | - |
| Capitalization / Revenue | - | - | - | - | 18.9x | 1.25x |
| EV / Revenue | - | - | - | - | 9.01x | -22.6x |
| EV / EBITDA | - | - | - | - | -6.04x | 3.66x |
| EV / EBIT | - | - | - | - | -5.85x | 3.62x |
| EV / FCF | - | - | - | - | -5.69x | 5.44x |
| FCF Yield | - | - | - | - | -17.6% | 18.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.177 | -2.824 | -0.519 | -1.397 | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 4.778 | 2.602 | 1.972 | 1.928 | 1.741 | 1.138 |
| EBITDA 1 | -1.852 | -4.87 | -5.008 | -1.889 | -2.598 | -7.049 |
| EBIT 1 | -2.197 | -5.19 | -5.258 | -2.092 | -2.68 | -7.123 |
| Net income 1 | -2.748 | -5.736 | -5.935 | -3.099 | -3.304 | -6.205 |
| Net Debt 1 | -0.6256 | -4.328 | -8.408 | -8.375 | -17.25 | -27.2 |
| Reference price 2 | 9,200,000,000.000 | 1,400,000,000.000 | 67,523,809.524 | 16,122,840.691 | 2,993,999.760 | 13,440.000 |
| Nbr of stocks (in thousands) | - | - | - | - | 0.01 | 0.11 |
| Announcement Date | 13/08/21 | 18/07/22 | 31/07/23 | 13/08/24 | 31/07/25 | 01/07/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 46.91K | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 29.58x | 7.09x | 18.77x | 2.12% | 402.75B | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SXTC Stock
- Valuation China SXT Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
